PNC27
Also known as: PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
Preclinical p53-derived peptide investigated in laboratory cancer research
Status
Preclinical
Typical dose
No human dose - research compound only
Researched for
Cancer research; tumor targeting; oncology research.
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
Preclinical - Promising animal research, limited human data
Use the tools
Stay current
Get updates on PNC27
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- An engineered 32-amino-acid incorporating p53 residues 12–26 and a membrane-entry leader.
- The source reports membrane-targeting, lytic effects in laboratory cancer models, including in-vitro and ex-vivo work.
- Evidence is ; no completed human clinical trials or FDA approval are reported.
How it's thought to work
The source describes a p53-derived binding segment engaging HDM-2/MDM2 reported at the surface of some cancer cells. It proposes that the 's amphipathic helix-loop-helix conformation can enter the membrane and form pores, leading to necrotic lysis rather than apoptosis. It also reports mitochondrial membrane disruption after entry. Reported selectivity is attributed to normal cells lacking membrane-associated HDM-2, but this remains evidence.
What the research shows
Where the research stands
The source characterizes a 2010 PNAS report by Sarafraz-Yazdi and colleagues as evidence for HDM-2 binding and cancer-cell lysis, and it mentions a separate 2010 intact- lysis study. It also describes a 2022 Biomedicines publication as consistent with membrane-pore and selectivity findings in cell lines; according to the source, normal cells made to express membrane HDM-2 became susceptible. These accounts concern in-vitro, ex-vivo, and animal work. No completed human trial is reported to establish safety or anticancer benefit.
What it shows
✓ Animal studies
Promising animal research, limited human data
△ Limitations
Animal study doses may not translate directly to humans.
Bottom line: Preclinical; reported in-vitro, ex-vivo human cancer-tissue, and animal research, with no human clinical trials reported. The source reports that PNC27 lacks FDA approval.
Typical dosing
CommunityCommunity datasetNo human dose - research compound only
Not applicable - no human use
Range: Lab research: 0.1-0.3 mg/mL in cell culture
In cell-culture reports, 0.2-0.3 mg/mL was associated with 90-100 % cancer-cell killing while normal cells were described as spared. The source describes only cell-culture and ex-vivo work, not human clinical trials.
Research dosing
Animal studies onlyAnimal studies only - may not translate to humans
Doses observed in studies
0.3 mg/mL (nearly 100% leukemia cell killing)
Annals of Clinical & Laboratory Science 2014 - PNC-27 induces tumor cell necrosis in leukemia cells
Animal study doses may not translate directly to humans.
- Duration
- Research protocols only - no human use data
- Administration
- IV injection in animal studies - not for human use
Timing & administration
Best time to take
Per research protocol
Research protocols only
Food recommendation
With or without food (source-listed; no human-use basis supplied).
Why this timing?
The source describes a short half-life and cell-culture re-addition at a 24 hour interval, with activity reported as optimal at 37°C. This does not establish a human schedule.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Limited safety information is available for this research compound.
- The source reports in-vitro selectivity for cancer cells.
- No cytotoxicity was reported in normal fibroblasts and leukocytes.
- Reported activity was temperature dependent, with 37°C described as optimal and 17°C as minimal.
- No human clinical trials were reported.
- Systemic effects in humans are unknown.
- Potential immunogenicity is unknown.
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.